Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Holdings Lifted by JPMorgan Chase & Co.

JPMorgan Chase & Co. lifted its position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 239.8% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 16,391 shares of the company’s stock after acquiring an additional 11,567 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.11% of Jasper Therapeutics worth $308,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JSPR. BNP Paribas Financial Markets lifted its holdings in shares of Jasper Therapeutics by 208.6% in the third quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company’s stock valued at $47,000 after purchasing an additional 1,698 shares in the last quarter. Wolff Wiese Magana LLC acquired a new stake in Jasper Therapeutics during the 3rd quarter worth about $59,000. MetLife Investment Management LLC grew its stake in Jasper Therapeutics by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 6,874 shares of the company’s stock valued at $129,000 after acquiring an additional 3,873 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Jasper Therapeutics in the 3rd quarter valued at about $251,000. Finally, American Century Companies Inc. lifted its position in shares of Jasper Therapeutics by 27.1% in the second quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock worth $322,000 after purchasing an additional 3,032 shares in the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

Jasper Therapeutics stock opened at $6.70 on Friday. The company has a market capitalization of $100.50 million, a price-to-earnings ratio of -1.41 and a beta of 2.18. The company’s fifty day moving average price is $16.47 and its two-hundred day moving average price is $18.65. Jasper Therapeutics, Inc. has a one year low of $5.25 and a one year high of $31.01.

Jasper Therapeutics (NASDAQ:JSPR) last released its earnings results on Thursday, November 7th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.15). As a group, sell-side analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on JSPR shares. HC Wainwright lowered their price objective on shares of Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. JMP Securities restated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. BMO Capital Markets started coverage on Jasper Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $63.00 price objective for the company. Finally, Royal Bank of Canada lowered their target price on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating on the stock in a research note on Thursday, January 9th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $67.75.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.